Entera Bio (FRA:5DT) Total Assets : €9.42 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Total Assets?

Entera Bio's Total Assets for the quarter that ended in Mar. 2024 was €9.42 Mil.

During the past 12 months, Entera Bio's average Total Assets Growth Rate was 14.80% per year. During the past 3 years, the average Total Assets Growth Rate was -12.90% per year. During the past 5 years, the average Total Assets Growth Rate was -16.60% per year.

During the past 9 years, Entera Bio's highest 3-Year average Total Assets Growth Rate was 5.70%. The lowest was -18.60%. And the median was -11.75%.

Total Assets is connected with ROA %. Entera Bio's annualized ROA % for the quarter that ended in Mar. 2024 was -73.47%. Total Assets is also linked to Revenue through Asset Turnover. Entera Bio's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Entera Bio Total Assets Historical Data

The historical data trend for Entera Bio's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Total Assets Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

15.03

7.99

23.00

12.39

10.79

Entera Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															10.84	9.64	8.03	10.79	9.42

Entera Bio Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Entera Bio's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	9.524	+	1.265
	=	10.79

Entera Bio's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	8.154	+	1.266
	=	9.42

Entera Bio (FRA:5DT) Total Assets Explanation

Total Assets is connected with ROA %.

Entera Bio's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-7.424	/	( (10.789	+	9.42)	/ 2 )
	=	-7.424	/	10.1045
	=	-73.47 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Entera Bio's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (10.789	+	9.42)	/ 2 )
=	0	/	10.1045
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Entera Bio Total Assets Related Terms

Thank you for viewing the detailed overview of Entera Bio's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio (FRA:5DT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ENTX:USA

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines